Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNM002 vs HTIG for Tetanus Prophylaxis
NCT05664750Phase 3Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of siltartoxatug in Tetanus (2 arms), sponsored by Trinomab Pharmaceutical. Primary endpoint: Percentage of Participants With ∆Titers ≥0.01 IU/mL at 12 hours. Started Dec 2022; status: completed.
02
Drugs
siltartoxatug
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT05664750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664750.